Biochemical Evaluation by Confirmatory Tests after Unilateral Adrenalectomy for Primary Aldosteronism

Table 4

Clinical outcome.

	Variables	Clinical outcome		value
		Complete	Partial
	Number of patients	6 (37.5%)	10 (62.5%)
	Age at Adx (year)			1.000
	Female/male sex	4/3	5/5	0.633
Before Adx	Presence of hypokalemia (%)	67	40	0.608
	SBP (mmHg)			0.478
	DBP (mmHg)			0.356
	Medication (defined daily dose)			0.022
	eGFR (mL/min/1.73 m^2)			0.626
	Basal PRA (ng/mL/h)			0.175
	Basal PAC (ng/dL)			0.148
	Basal ARR			0.212
	U-Aldo (μg/day)			0.651
	AVS (yes/no)	6/0	9/1	1.000
	AVS (yes/no)	5/1	8/2	1.000
	Tumor detected by CT (yes/no)	5/1	7/3	1.000
	Side for Adx (left/right)	3/3	7/3	0.607
After Adx	Evaluation time after Adx (month)			0.410
	Presence of hypokalemia (%)	0	0
	SBP (mmHg)			1.000
	DBP (mmHg)			0.956
	Medication (defined daily dose)			0.001
	eGFR (mL/min/1.73 m2)			0.704
	Basal PRA (ng/mL/h)			0.057
	Basal PAC (ng/dL)			0.058
	Basal ARR			0.481
	U-Aldo (μg/day)	3		0.175
	Histological diagnosis (adenoma/cortical nodule)	5/1	9/1	1.000

Adx: unilateral adrenalectomy; SBP: systolic blood pressure; DBP: diastolic blood pressure; Medication: antihypertensive medication; eGFR: estimated glomerular filtration rate; PRA: plasma renin activity; PAC: plasma aldosterone concentration; ARR: aldosterone-renin ratio; U-Aldo: 24 h urine aldosterone; AVS: adrenal venous sampling; LR: lateralized ratio; CR: contralateral ratio; CT: computed tomography. Data are presented as deviation. The Wilcoxon signed-rank test or Fisher’s exact test is performed. value < 0.05.